Diamyd-licensed technology enhances transplanted human beta cell mass in preclinical model of type 1 diabetes
Diamyd Medical (Nasdaq Stockholm First North, Ticker: DMYD B) informs that a new scientific paper in the December issue of the journal Diabetes shows that GABA enhances transplanted human beta cell mass in the NOD mouse model of type 1 diabetes. Diamyd Medical licenses exclusive rights from the University of California for the therapeutic use of GABA for the treatment of diabetes and other inflammation-related conditions.The paper shows that GABA (gamma amino butyric acid) enhances beta cell mass in the NOD mouse model of type 1 diabetes following transplantation of human pancreatic insulin